2023
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)
Ruddy K, Zahrieh D, He J, Waechter B, Holleran J, Lewis L, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo H, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars In Oncology 2023, 50: 7-10. PMID: 36693773, PMCID: PMC10247389, DOI: 10.1053/j.seminoncol.2023.01.001.Peer-Reviewed Original ResearchConceptsMTOR inhibitor-associated stomatitisDexamethasone mouthwashCoprimary endpointsTrough concentrationsExact testRandomized phase III trialEverolimus trough concentrationsPrior clinical researchPhase III trialsDose-limiting toxicityFisher's exact testMann-Whitney U testWilcoxon rank sum testRank sum testOral everolimusIII trialsOral stomatitisTreatment periodMouth rinseMTOR inhibitorsPoor enrollmentClinical researchEverolimusU testStomatitis
2014
Treatment‐Related Mortality With Everolimus in Cancer Patients
Wesolowski R, Abdel‐Rasoul M, Lustberg M, Paskell M, Shapiro C, Macrae E. Treatment‐Related Mortality With Everolimus in Cancer Patients. The Oncologist 2014, 19: 661-668. PMID: 24794158, PMCID: PMC4041666, DOI: 10.1634/theoncologist.2013-0355.Peer-Reviewed Original ResearchConceptsFatal adverse eventsTreatment-related mortalityCancer patientsAdverse eventsOverall incidenceSan Antonio Breast Cancer SymposiumRole of everolimusControl group patientsMultiple solid tumorsEverolimus administrationGroup patientsCancer SymposiumSubgroup analysisControl armOdds ratioEverolimusFatal eventsClinical OncologyPatientsSolid tumorsPubMed databaseTumor typesIncidenceAmerican SocietySignificant differences